Wilmslow, United Kingdom

Paul Workman

This inventor holds 1 USPTO granted patent. Top assignee: Sri International. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul Workman: Innovator in Tumor Detection

Introduction

Paul Workman is a notable inventor based in Wilmslow, GB. He has made significant contributions to the field of cancer research, particularly in the detection of hypoxic tumor cells. His innovative work has led to the development of novel compounds that can aid in the diagnosis and treatment of cancer.

Latest Patents

Paul Workman holds 1 patent for his invention titled "Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells." This patent provides agents that are useful for detecting hypoxic tumor cells. The compounds he developed have a specific structural formula and include methods for using these compounds in clinical settings. Additionally, pharmaceutical compositions formulated with these novel compounds are also part of his patent.

Career Highlights

Throughout his career, Paul Workman has been associated with Sri International, where he has worked on various research projects aimed at improving cancer detection methods. His expertise in the field has made him a valuable asset to the organization.

Collaborations

Paul has collaborated with notable colleagues, including Andrew B Kelson and Michael Tracy. Their combined efforts have contributed to advancements in cancer research and detection technologies.

Conclusion

Paul Workman is a distinguished inventor whose work in detecting hypoxic tumor cells has the potential to significantly impact cancer diagnosis and treatment. His innovative approach and collaboration with other experts in the field highlight the importance of teamwork in scientific advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…